SPIMACO

🌟 Celebrating Team Spirit at SPIMACO! 🌟 As we bid farewell to 2024, we want to take a moment to reflect on the incredible teamwork and dedication that have shaped our success this year. Across our #KSA facilities, we’ve embraced a range of engaging activities that highlight the strength of our collaboration and the positive work environment we’ve built together. From team-building events to innovative initiatives, we’ve focused on creating a space where our people thrive. These efforts are a testament to the shared commitment to excellence and well-being that drives us forward at SPIMACO. 💬 Watch the video to see the highlights of our team engagement activities and get a glimpse of the vibrant culture we continue to nurture. We’re excited for what’s ahead and look forward to even more meaningful achievements in 2025. Happy New Year 2025 from #SPIMACO! 🎉

🌟 Spotlight on SPIMACO's R&D Department: Paving the Way for Regulatory Excellence 🌟 At #SPIMACO, our Research and Development (R&D) department plays a crucial role in the product registration process with the Saudi Food and Drug Authority (SFDA - هيئة الغذاء والدواء), ensuring that all our products meet the highest standards of safety, efficacy, and quality. The R&D team works diligently to develop innovative solutions, conduct comprehensive testing, and provide the necessary scientific data required for seamless regulatory approval. Their expertise is vital in navigating the complex regulatory landscape, ensuring timely registration, and bringing new, life-changing products to the market for the benefit of patients in #SaudiArabia. Together, we continue to build a healthier future for Saudi Arabia and beyond through #science, #innovation, and #dedication. 🚀

🌟 Proud Moment for #SPIMACO: A Milestone in #Biotechnology 🌟 We are thrilled to announce that SPIMACO has successfully produced Saudi Arabia’s first-ever biosimilar product fully manufactured within the Kingdom! 🇸🇦💉 This groundbreaking achievement marks a significant step forward in SPIMACO's commitment to driving #innovation and advancing the #pharmaceutical sector in #SaudiArabia. By producing #biosimilars locally, we not only contribute to enhancing #healthcare access but also play a key role in strengthening the local pharmaceutical industry. This milestone showcases our dedication to #quality, scientific excellence, and the #growth of the Saudi healthcare ecosystem. Together, we continue to shape a healthier future for Saudi Arabia and beyond! 🚀

🌟 SPIMACO Academy - "Beyond the Campus" Session: Phase Two 🌟 We are excited to announce the successful completion of the second phase of our #SPIMACO Academy - "Beyond the Campus" session! 🚀 Following the success of the first batch, which took place on November 26th, we welcomed another group of talented graduates and final-year pharmacy students from across #SaudiArabia. This session, held at our Riyadh HQ, continues to bridge the gap between academic learning and industry experience, offering participants real-world insights into the pharmaceutical sector. As part of SPIMACO’s ongoing #CSR efforts, this initiative is designed to empower the next generation of pharmaceutical professionals by providing them with the #knowledge, #skills, and confidence to succeed in the #industry. We are thrilled to have had students from top universities across the Kingdom, including: King Saud University Princess Nourah Bint Abdulrahman University Imam Abdulrahman Bin Faisal University Al Qasimia University Al Baha University King AbdulAziz University Al Yamamah University Prince Sattam bin Abdulaziz University University of Tabuk Shaqra University Umm Al-Qura University Al Maarefah University This marks an important step in our mission to shape the future of #healthcare by fostering local talent and contributing to the growth of the #pharmaceutical sector in Saudi Arabia. We are already looking forward to the third phase and the incredible impact it will have on our future healthcare leaders.

🌟 Spotlight on Dammam Pharma: Excellence in Manufacturing 🌟 At #SPIMACO, we are proud to have Dammam Pharma as one of our key subsidiaries, specializing in the manufacturing of oral tablets and capsules. 💊✨ With a focus on #quality, #innovation, and #reliability, #DammamPharma plays a crucial role in supporting our mission to provide high-quality healthcare solutions to the region. Their dedication to excellence is reflected in their #ISO and #GMP certifications, ensuring that every product meets the highest global standards. 🔗 Attached: ISO & GMP Certificates – a testament to Dammam Pharma's commitment to quality and compliance. We look forward to the continued success of Dammam Pharma as they help us drive forward our vision of #healthcare excellence in #SaudiArabia and beyond.

🌟 Exciting Announcement: SPIMACO and Organon Join Forces to Localize Products in Saudi Arabia 🌟 We are thrilled to share that #SPIMACO has officially signed a Memorandum of Understanding (MoU) with Organon during the #CPHI Middle East Exhibition to localize pharmaceutical products right here in #SaudiArabia! 🤝🇸🇦 This strategic partnership marks a significant milestone in our commitment to enhancing #healthcare access and expanding our local capabilities. Together, SPIMACO and #Organon aim to bring innovative and high-quality treatments to Saudi patients, empowering local manufacturing and driving healthcare advancements in the region. 🔗 Watch the video below to see highlights from the MoU signing ceremony, including a statement from Organon’s Country Lead, Mohamad Holayl, who shared their vision for this collaboration. We look forward to this promising journey ahead and the positive impact it will have on the healthcare sector in Saudi Arabia. 🚀

We are thrilled to share that #SPIMACO has signed a Memorandum of Understanding (MoU) with Boston Oncology Arabia, marking an exciting step forward in localizing oral oncology products and transferring technology and knowledge. This significant collaboration, announced during the #CPHI Middle East exhibition, aligns perfectly with #SaudiArabia's Vision 2030, which focuses on advancing local content development and boosting national industrial capabilities to ensure pharmaceutical security. In the attached video, a statement was made by SPIMACO's CEO, Jérôme Cabannes, and Boston Oncology Arabia's CEO, Abdullah Baaj, MD, PharmD. We look forward to the positive impact this partnership will have on the healthcare sector and the continued progress of the Kingdom’s pharmaceutical industry.

🌟 Celebrating Four Decades of Pioneering Excellence in the MENA Region 🌟 As #SPIMACO marks nearly 40 years of leadership in the #MENA region, we are proud to share our journey of #innovation, #growth, and #success. From our humble beginnings to becoming the trusted name in the #pharmaceutical industry, we’ve continuously strived for #excellence, pushing boundaries and setting new standards. These milestones reflect our commitment to improving #healthcare across the region. Thank you to our dedicated team, partners, and stakeholders for contributing to this incredible journey. Here's to many more years of growth, leadership, and innovation in the pharmaceutical industry. 🚀

🚀 Driving SPIMACO’s Future: Innovation & Excellence in R&D 🔬 At #SPIMACO, our commitment to advancing healthcare is driven by the brilliant minds in our Research & Development (R&D) department. As a leader in the pharmaceutical industry, we understand that the future of healthcare depends on continuous #innovation and a dedication to improving lives. Our R&D team plays a pivotal role in shaping SPIMACO’s success. From developing groundbreaking solutions, to optimizing drug formulations, our experts work tirelessly to meet the evolving #healthcare needs of today and tomorrow. 💡 What Sets SPIMACO’s R&D Apart? Innovative Research: Pioneering treatments to improve patient outcomes. State-of-the-Art Facilities: Equipped with the latest technology for advanced drug development. Collaborative Culture: Fostering innovation through partnerships with institutions and universities. Commitment to Quality: Rigorous testing to ensure the highest standards of safety and effectiveness. As we move forward, SPIMACO’s R&D department remains at the forefront of shaping the future of #pharmaceuticals, continuously driving innovation, and contributing to a healthier tomorrow.

🌟 #SPIMACO's Investment in CAD Middle East: Pioneering API Manufacturing in the Region 🌟 We are proud to spotlight one of our strategic investments, CAD Middle East Pharmaceutical Industries LLC, the only #API (Active Pharmaceutical Ingredient) manufacturer in the #MiddleEast! As part of our ongoing commitment to advancing pharmaceutical manufacturing capabilities, CAD Middle East strives to bring cutting-edge solutions, ensuring high-quality, locally produced #APIs that meet the growing demands of the region and beyond. With a relentless focus on #innovation, #quality, and #sustainability, CAD Middle East plays a vital role in shaping the future of the pharmaceutical industry in the region. 👉 Stay tuned for the attached design showcasing CAD Middle East’s vision and mission, highlighting their commitment to excellence and driving the pharmaceutical industry forward.